Eledon Pharmaceuticals (ELDN)
Develops tegoprubart for transplant rejection and CD40L-linked immune disease.
$3.06
Pre-market+0.08 (+2.51%)
At close$2.99(−0.83%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions168 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 57.56% | 46.77M shares | |
| Insiders10 holders · as of Aug 4, 2026 | 1.30% | 1.06M shares | |
| Otherremainder | ≈ 41.14% | 33.43M shares |
81.26M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Institutions13F, as of Jun 30, 2026
168 holders · 46.77M shares · 50 new positions · 113 increased · 23 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BVF Inc/IL | 6.29M | 7.74% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 5.12M | 6.31% | +741.6K | Aug 7, 2026 |
| Defilade Capital Management, L.P. | 3.53M | 4.34% | −38.8K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.42M | 4.21% | +124.1K | Aug 13, 2026 |
| Goldman Sachs Group Inc | 2.51M | 3.09% | +2.14M | Aug 14, 2026 |
| Ensign Peak Advisors, Inc | 2.10M | 2.59% | −363.7K | Aug 14, 2026 |
| Geode Capital Management, LLC | 1.96M | 2.41% | +164.8K | Aug 12, 2026 |
| Catalio Capital Management, LP | 1.70M | 2.09% | +55.3K | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Biotechnology Value Fund L P | 6.80% | 5.38M | 13G | May 15, 2026 ↗ |
| Patrick J. Heronincl. Fhmls Xi, L.L.C., Frazier Life Sciences X, L.P. +14 more | 6.10% | 3.56M | 13G | Nov 5, 2024 ↗ |
| RA Capital Healthcare Fund, L.P.incl. RA Capital Management, L.P., Rajeev Shah +1 more | 6.10% | 3.57M | 13G | Nov 5, 2024 ↗ |
| BlackRock, Inc. | 5.80% | 4.38M | 13G | Apr 27, 2026 ↗ |
| Vanguard Capital Management | 5.05% | 3.90M | 13G | Jul 31, 2026 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.
